Trial Profile
(Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Betrixaban (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APEX
- Sponsors Portola Pharmaceuticals
- 01 Feb 2023 Results assessing the Age-D-dimer-Albumin score for predicting thrombosis in a non-COVID-19 medically ill population from the APEX trial, published in the Journal of Thrombosis and Thrombolysis.
- 01 Mar 2022 Results published in the Thrombosis Research
- 08 Aug 2019 Results published in the Journal of Thrombosis and Haemostasis